New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

[1] Baggstrom MQ(2017)Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance) J Thorac Oncol 12 843-849

[2] Socinski MA(2013)Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089) J Clin Oncol 31 3004-3011

[3] Wang XF(2007)Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy J Immunol 178 1505-1511

[4] Barlesi F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[5] Scherpereel A(2011)Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind Phase III trial J Clin Oncol 29 1067-1074

[6] Rittmeyer A(2008)The role of the EGFR signaling in tumor microenvironment J Cell Physiol 214 559-567

[7] Bouzin C(2015)Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer Cancer 121 883-892

[8] Brouet A(2008)Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Clin Cancer Res 14 6674-6682

[9] De Vriese J(1971)Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182-1186

[10] Dewever J(1972)Anti-angiogenesis: new concept for therapy of solid tumors Ann Surg 175 409-416

[1] Baggstrom MQ(2017)Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance) J Thorac Oncol 12 843-849

[2] Socinski MA(2013)Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089) J Clin Oncol 31 3004-3011

[3] Wang XF(2007)Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy J Immunol 178 1505-1511

[4] Barlesi F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[5] Scherpereel A(2011)Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind Phase III trial J Clin Oncol 29 1067-1074

[6] Rittmeyer A(2008)The role of the EGFR signaling in tumor microenvironment J Cell Physiol 214 559-567

[7] Bouzin C(2015)Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer Cancer 121 883-892

[8] Brouet A(2008)Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Clin Cancer Res 14 6674-6682

[9] De Vriese J(1971)Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182-1186

[10] Dewever J(1972)Anti-angiogenesis: new concept for therapy of solid tumors Ann Surg 175 409-416